Details of the Drug

General Information of Drug (ID: DMHYLQ2)

Drug Name

Lithium chloride

Synonyms

LITHIUM CHLORIDE; 7447-41-8; Lithiumchloride; Lithium chloride (LiCl); LiCl; chlorure de lithium; Chlorku litu; chlorolithium; Lithiumchlorid; Chlorku litu [Polish]; Luthium chloride; Chlorure de lithium [French]; CCRIS 5924; UNII-G4962QA067; HSDB 4281; EINECS 231-212-3; lithium(1+) ion chloride; NSC 327172; CHEMBL69710; CHEBI:48607; NSC327172; MFCD00011078; G4962QA067; Lithium chloride, 99%, extra pure; ClLi; Lithium chloride, 99+%, ACS reagent; Lithium chloride, 99%, for molecular biology; Lithium chloride, 99%, for analysis, anhyd

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

42.4

Logarithm of the Partition Coefficient

Not Available

Rotatable Bond Count

Hydrogen Bond Donor Count

Hydrogen Bond Acceptor Count

Chemical Identifiers

Formula: ClLi
IUPAC Name: lithium;chloride
Canonical SMILES: [Li+].[Cl-]
InChI: InChI=1S/ClH.Li/h1H;/q;+1/p-1
InChIKey: KWGKDLIKAYFUFQ-UHFFFAOYSA-M

Cross-matching ID

PubChem CID: 433294
ChEBI ID: CHEMBL69710
CAS Number: 7447-41-8
UNII: G4962QA067
DrugBank ID: DB16607
TTD ID: D07WXT

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glycogen synthase kinase-3 alpha (GSK-3A)	TTRZQE3	GSK3A_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B)	OTOA8WU2	PDE4B_HUMAN	Gene/Protein Processing	[2]
4-aminobutyrate aminotransferase, mitochondrial (ABAT)	OTXAGR7J	GABT_HUMAN	Gene/Protein Processing	[3]
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Gene/Protein Processing	[2]
Abl interactor 2 (ABI2)	OT8GIIS5	ABI2_HUMAN	Gene/Protein Processing	[2]
Adenomatous polyposis coli protein 2 (APC2)	OTRH91CX	APCL_HUMAN	Gene/Protein Processing	[2]
Adhesion G protein-coupled receptor B3 (ADGRB3)	OT1EWGRW	AGRB3_HUMAN	Gene/Protein Processing	[3]
Adhesion G protein-coupled receptor E5 (ADGRE5)	OTTSB84Q	AGRE5_HUMAN	Gene/Protein Processing	[2]
ADP-ribosylation factor 6 (ARF6)	OTVV7KJO	ARF6_HUMAN	Gene/Protein Processing	[3]
Alkaline phosphatase, germ cell type (ALPG)	OTCIM29R	PPBN_HUMAN	Gene/Protein Processing	[2]
Alkaline phosphatase, placental type (ALPP)	OTZU4G9W	PPB1_HUMAN	Gene/Protein Processing	[4]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6.
2	Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
3	Early gene response in lithium chloride induced apoptosis. Apoptosis. 2005 Jan;10(1):75-90. doi: 10.1007/s10495-005-6063-x.
4	P53 and beta-catenin activity during estrogen treatment of osteoblasts. Cancer Cell Int. 2005 Jul 29;5:24. doi: 10.1186/1475-2867-5-24.